Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Global Outlook and Forecast 2022-2028

March 2022 | 64 pages | ID: HE4C2F791677EN
Market Monitor Global

Abstracts

Hypertrophic Cardiomyopathy (HCM) is a condition in which a portion of the heart becomes thickened without an obvious cause. This results in the heart being less able to pump blood effectively. Symptoms vary from none to feeling tired, leg swelling, and shortness of breath. It may also result in chest pain or fainting.

This report contains market size and forecasts of Hypertrophic Cardiomyopathy (HCM) Therapeutics in Global, including the following market information:

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Hypertrophic Cardiomyopathy (HCM) Therapeutics market was valued at 1062.8 million in 2021 and is projected to reach US$ 1249.1 million by 2028, at a CAGR of 2.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Beta Adrenergic Blocking Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hypertrophic Cardiomyopathy (HCM) Therapeutics include AstraZeneca, Concordia International, Gilead Sciences, Merck, Mylan, Novartis, Pfizer, Sanofi and Teva Pharmaceutical Industries. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hypertrophic Cardiomyopathy (HCM) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Beta Adrenergic Blocking Agents
• Calcium Channel Blockers
• Antiarrhythmic Agents
• Anticoagulants
• Others

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacies
• Retail Pharmacies

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hypertrophic Cardiomyopathy (HCM) Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Hypertrophic Cardiomyopathy (HCM) Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AstraZeneca
• Concordia International
• Gilead Sciences
• Merck
• Mylan
• Novartis
• Pfizer
• Sanofi
• Teva Pharmaceutical Industries

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL HYPERTROPHIC CARDIOMYOPATHY (HCM) THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size: 2021 VS 2028
2.2 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Hypertrophic Cardiomyopathy (HCM) Therapeutics Players in Global Market
3.2 Top Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies Ranked by Revenue
3.3 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Beta Adrenergic Blocking Agents
  4.1.3 Calcium Channel Blockers
  4.1.4 Antiarrhythmic Agents
  4.1.5 Anticoagulants
  4.1.6 Others
4.2 By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacies
  5.1.3 Retail Pharmacies
5.2 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028
  6.3.2 US Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.3.3 Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028
  6.4.2 Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.4.3 France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.4.5 Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.4.6 Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028
  6.5.2 China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.5.3 Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.5.6 India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.7.3 Israel Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028
  6.7.5 UAE Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AstraZeneca
  7.1.1 AstraZeneca Corporate Summary
  7.1.2 AstraZeneca Business Overview
  7.1.3 AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  7.1.4 AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 AstraZeneca Key News
7.2 Concordia International
  7.2.1 Concordia International Corporate Summary
  7.2.2 Concordia International Business Overview
  7.2.3 Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  7.2.4 Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Concordia International Key News
7.3 Gilead Sciences
  7.3.1 Gilead Sciences Corporate Summary
  7.3.2 Gilead Sciences Business Overview
  7.3.3 Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  7.3.4 Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Gilead Sciences Key News
7.4 Merck
  7.4.1 Merck Corporate Summary
  7.4.2 Merck Business Overview
  7.4.3 Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  7.4.4 Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Merck Key News
7.5 Mylan
  7.5.1 Mylan Corporate Summary
  7.5.2 Mylan Business Overview
  7.5.3 Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  7.5.4 Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 Mylan Key News
7.6 Novartis
  7.6.1 Novartis Corporate Summary
  7.6.2 Novartis Business Overview
  7.6.3 Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  7.6.4 Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Novartis Key News
7.7 Pfizer
  7.7.1 Pfizer Corporate Summary
  7.7.2 Pfizer Business Overview
  7.7.3 Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  7.7.4 Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Pfizer Key News
7.8 Sanofi
  7.8.1 Sanofi Corporate Summary
  7.8.2 Sanofi Business Overview
  7.8.3 Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  7.8.4 Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 Sanofi Key News
7.9 Teva Pharmaceutical Industries
  7.9.1 Teva Pharmaceutical Industries Corporate Summary
  7.9.2 Teva Pharmaceutical Industries Business Overview
  7.9.3 Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  7.9.4 Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Teva Pharmaceutical Industries Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Opportunities & Trends in Global Market
Table 2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Drivers in Global Market
Table 3. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Restraints in Global Market
Table 4. Key Players of Hypertrophic Cardiomyopathy (HCM) Therapeutics in Global Market
Table 5. Top Hypertrophic Cardiomyopathy (HCM) Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Type
Table 9. List of Global Tier 1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. AstraZeneca Corporate Summary
Table 31. AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings
Table 32. AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Concordia International Corporate Summary
Table 34. Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings
Table 35. Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Gilead Sciences Corporate Summary
Table 37. Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings
Table 38. Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Merck Corporate Summary
Table 40. Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings
Table 41. Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Mylan Corporate Summary
Table 43. Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings
Table 44. Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Novartis Corporate Summary
Table 46. Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings
Table 47. Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Pfizer Corporate Summary
Table 49. Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings
Table 50. Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Sanofi Corporate Summary
Table 52. Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings
Table 53. Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Teva Pharmaceutical Industries Corporate Summary
Table 55. Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings
Table 56. Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Hypertrophic Cardiomyopathy (HCM) Therapeutics Segment by Type in 2021
Figure 2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Segment by Application in 2021
Figure 3. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in 2021
Figure 8. By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)